Drugs / Treprilimab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04534855 | Sep 2020 → Sep 2022 | nasopharyngeal carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Treprilimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04534855 ↗ |
| Modality | Monoclonal antibody | “anti-programmed death 1 receptor monoclonal antibody” NCT04534855 ↗ |
| Route | Intravenous | “240mg intravenously” NCT04534855 ↗ |